At-home genetic kits don't reveal all breast cancer risks

Millions of people have bought into the mail-in DNA testing craze, but a new study indicates consumers should be aware of the limitations of the health tests offered.   Those who expect 23andMe to detect most breast cancer risks are being cautioned after study findings determined almost 90 percent of participants with a BRCA mutation wouldn’t have received a positive from the company’s test, reports The New York Times. The test’s limited scope is to bla me, per The Daily Beast. The study,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news